Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 12415

1.

CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion.

Martín-Cortázar C, Chiodo Y, Jiménez-P R, Bernabé M, Cayuela ML, Iglesias T, Campanero MR.

Haematologica. 2019 Jun 20. pii: haematol.2018.215459. doi: 10.3324/haematol.2018.215459. [Epub ahead of print]

2.

The promise of CD4+FoxP3+ regulatory T cell manipulation in vivo: applications for allogeneic hematopoietic stem cell transplantation.

Copsel S, Wolf D, Komanduri KV, Levy RB.

Haematologica. 2019 Jun 20. pii: haematol.2018.198838. doi: 10.3324/haematol.2018.198838. [Epub ahead of print]

3.

Chimeric antigen receptor T-cell therapy for acute myeloid leukaemia : How close to reality?

Cummins KD, Gill S.

Haematologica. 2019 Jun 20. pii: haematol.2018.208751. doi: 10.3324/haematol.2018.208751. [Epub ahead of print]

4.

Respiratory syncytial virus in hematopoietic cell transplant recipients and hematologic malignancy patients.

Khawaja F, Chemaly RF.

Haematologica. 2019 Jun 20. pii: haematol.2018.215152. doi: 10.3324/haematol.2018.215152. [Epub ahead of print]

5.

Microhomology-mediated end joining drives complex rearrangements and over expression of MYC and PVT1 in multiple myeloma.

Mikulasova A, Ashby C, Tytarenko RG, Qu P, Rosenthal A, Dent JA, Ryan KR, Bauer MA, Wardell CP, Hoering A, Mavrommatis K, Trotter M, Deshpande S, Yaccoby S, Tian E, Keats J, Auclair D, Jackson GH, Davies FE, Thakurta A, Morgan GJ, Walker BA.

Haematologica. 2019 Jun 20. pii: haematol.2019.217927. doi: 10.3324/haematol.2019.217927. [Epub ahead of print]

6.

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.

Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O' Rourke L, Dimopoulos MA.

Haematologica. 2019 Jun 20. pii: haematol.2019.217448. doi: 10.3324/haematol.2019.217448. [Epub ahead of print]

7.

Variable global distribution of cell-of-origin from the ROBUST phase 3 study in diffuse large B-cell lymphoma.

Nowakowski GS, Chiappella A, Witzig TE, Scott DW, Spina M, Gascoyne RD, Zhang L, Russo J, Kang J, Zhang J, Xu Y, Vitolo U.

Haematologica. 2019 Jun 20. pii: haematol.2019.220475. doi: 10.3324/haematol.2019.220475. [Epub ahead of print]

8.

Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma.

Sun F, Cheng Y, Walsh SA, Acevedo MR, Jing X, Han SS, Pisano MD, Tomasson MH, Lichtenstein AK, Zhan F, Hari P, Janz S.

Haematologica. 2019 Jun 20. pii: haematol.2019.221127. doi: 10.3324/haematol.2019.221127. [Epub ahead of print]

9.

The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation.

Chatonnet F, Pignarre A, Sérandour AA, Caron G, Avner S, Robert N, Kassambara A, Laurent A, Bizot M, Agirre X, Prosper F, Martin-Subero JI, Moreaux J, Fest T, Salbert G.

Haematologica. 2019 Jun 20. pii: haematol.2019.222133. doi: 10.3324/haematol.2019.222133. [Epub ahead of print]

10.

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.

Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M.

Haematologica. 2019 Jun 20. pii: haematol.2019.219139. doi: 10.3324/haematol.2019.219139. [Epub ahead of print]

11.

Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation.

Bonnet P, Chasset F, Moguelet P, Abisror N, Itzykson R, Bouaziz JD, Hirsch P, Barbaud A, Haroche J, Mekinian A, Hélias-Rodzewicz Z, Clappier E, Fenaux P, Fain O, Tazi A, Emile JF; EMSED and MINHEMON.

Haematologica. 2019 Jun 20. pii: haematol.2019.223552. doi: 10.3324/haematol.2019.223552. [Epub ahead of print]

12.

RAC1/2 activation promotes FGFR1 driven leukemogenesis in stem cell leukemia/lymphoma syndrome.

Hu T, Chong Y, Lu S, McGuinness M, Williams DA, Cowell JK.

Haematologica. 2019 Jun 20. pii: haematol.2018.208058. doi: 10.3324/haematol.2018.208058. [Epub ahead of print]

13.

High-throughput platelet spreading analysis: a tool for the diagnosis of platelet- based bleeding disorders.

Khan AO, Maclachlan A, Lowe GC, Nicolson PLR, Al Ghaithi R, Thomas SG, Watson SP, Pike JA, Morgan NV; UK GAPP Study Group.

Haematologica. 2019 Jun 20. pii: haematol.2019.225912. doi: 10.3324/haematol.2019.225912. [Epub ahead of print]

14.

Clinical characteristics and outcomes of Richter transformation: Experience of 204 patients from a single center.

Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, Kay NE, Muchtar E, Van Dyke DL, Koehler AB, Schwager SM, Slager SL, Parikh SA, Ding W.

Haematologica. 2019 Jun 13. pii: haematol.2019.224121. doi: 10.3324/haematol.2019.224121. [Epub ahead of print]

15.

Sequential cellular niches control the generation of enucleated erythrocytes from human pluripotent stem cells.

Shen J, Zhu Y, Lyu C, Feng Z, Lyu S, Zhao Y, Hoyle DL, Ji G, Miao W, Zhang X, Cheng L, Brodsky RA, Cheng T, Wang ZZ.

Haematologica. 2019 Jun 13. pii: haematol.2018.211664. doi: 10.3324/haematol.2018.211664. [Epub ahead of print]

16.

Variable readthrough responsiveness of nonsense mutations in hemophilia A.

Martorell L, Cortina V, Parra R, Barquinero J, Vidal F.

Haematologica. 2019 Jun 13. pii: haematol.2018.212118. doi: 10.3324/haematol.2018.212118. [Epub ahead of print]

17.

Ephrin/Eph receptor interaction facilitates macrophage recognition of differentiating human erythroblasts.

Hampton-O'Neil LA, Severn CE, Cross SJ, Gurung S, Nobes CD, Toye AM.

Haematologica. 2019 Jun 13. pii: haematol.2018.215160. doi: 10.3324/haematol.2018.215160. [Epub ahead of print]

18.

Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19.

Plesa A, Labussière-Wallet H, Hayette S, Salles G, Thomas X, Sujobert P.

Haematologica. 2019 Jun 13. pii: haematol.2019.225557. doi: 10.3324/haematol.2019.225557. [Epub ahead of print]

19.

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK cell effector function in patients with mantle cell lymphoma.

Flinsenberg TWH, Tromedjo CC, Hu N, Liu Y, Guo Y, Thia KYT, Noori T, Song X, Aw Yeang HX, Tantalo DG, Handunnetti S, Seymour JF, Roberts AW, Ritchie D, Koldej R, Neeson PJ, Wang L, Trapani JA, Tam CS, Voskoboinik I.

Haematologica. 2019 Jun 6. pii: haematol.2019.220590. doi: 10.3324/haematol.2019.220590. [Epub ahead of print]

20.

Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus.

Blez D, Blaize M, Soussain C, Boissonnas A, Meghraoui-Kheddar A, Menezes N, Portalier A, Combadière C, Leblond V, Ghez D, Fekkar A.

Haematologica. 2019 Jun 6. pii: haematol.2019.219220. doi: 10.3324/haematol.2019.219220. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center